PGEN Q3 Earnings Call Highlights Launch Momentum and Competition - Zacks Investment Research
PGEN Q3 Earnings Call Highlights Launch Momentum and Competition - Zacks Investment Research(摘要待生成)
Precigen (PGEN) Q3 2026 Earnings Call Transcript
Precigen management said PAPZIMEOS net product revenue was $72.9 million in the third quarter, up about 37% from the second quarter. [[fact:fact-2haa9wq4p]] Management also reported third-quarter net income of $35.8 million. [[fact:fact-eutvvyn85]] The company said it generated $11.9 million in cash from operating activities in the third quarter. [[fact:fact-pqyssz3lu]] Management said more than 500 patients had begun PAPZIMEOS treatment by the call date. [[fact:fact-g41y3lceu]]
Precigen Gears Up to Report Q3 Earnings: What Can Investors Expect? - Yahoo Finance
Precigen Gears Up to Report Q3 Earnings: What Can Investors Expect? - Yahoo Finance(摘要待生成)
PGEN Stock Crashes Premarket: Retail Sees Buyout Opening As Inovio Rival Crashes The Party Before Earnings - Yahoo Finance
PGEN Stock Crashes Premarket: Retail Sees Buyout Opening As Inovio Rival Crashes The Party Before Earnings Yahoo Finance
Can Precigen (PGEN) Justify Its Valuation As Inovio Approval Tests Papzimeos?
Can Precigen (PGEN) Justify Its Valuation As Inovio Approval Tests Papzimeos? Yahoo Finance
Precigen (PGEN) Shares Drop 25% After Inovio's FDA Nod for Compe - GuruFocus
Precigen (PGEN) Shares Drop 25% After Inovio's FDA Nod for Compe GuruFocus
$PGEN stock is down 27% today. Here's what we see in our data. | PGEN Stock News
$PGEN stock is down 27% today. Here's what we see in our data. Quiver Quantitative